scholarly journals Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase ‐ a comparison of clinical and genetic characteristics

2021 ◽  
Vol 193 (3) ◽  
pp. 613-618
Author(s):  
Stephanie Sembill ◽  
Gudrun Göhring ◽  
Elke Schirmer ◽  
Friederike Lutterloh ◽  
Meinolf Suttorp ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
De Novo ◽  
Blast Phase ◽  
Genetic Characteristics

scholarly journals Deletion of MBD2 inhibits proliferation of chronic myeloid leukaemia blast phase cells

2018 ◽  
Vol 19 (8) ◽  
pp. 676-686 ◽  
Author(s):  
Ling Cheng ◽  
Ying Tang ◽  
Xing Chen ◽  
Lei Zhao ◽  
Songya Liu ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Blast Phase

scholarly journals Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia

2019 ◽  
Vol 115 ◽  
pp. 17-23 ◽  
Author(s):  
Frédéric Millot ◽  
Natacha Maledon ◽  
Joelle Guilhot ◽  
Adalet Meral Güneş ◽  
Krzysztof Kalwak ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
De Novo ◽  
Favourable Outcome

Effects of Imatinib Mesylate on Renin–Angiotensin System (RAS) Activity during the Clinical Course of Chronic Myeloid Leukaemia

2009 ◽  
Vol 37 (4) ◽  
pp. 1018-1028 ◽  
Author(s):  
M Sayitoglu ◽  
IC Haznedaroğlu ◽  
O Hatirnaz ◽  
Y Erbilgin ◽  
S Aksu ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Imatinib Mesylate ◽  
Kinase Inhibitors ◽  
De Novo ◽  
Renin Angiotensin System ◽  
Risk Groups ◽  
Mrna Levels ◽  
Angiotensin System ◽  
Renin Angiotensin

The renin–angiotensin system (RAS) is involved in cell growth, proliferation and differentiation in bone marrow in an autocrine–paracrine manner, and it modulates normal and neoplastic haematopoietic cell proliferation. This study aimed to assess expressions of the RAS components, renin, angiotensinogen and angiotensin-converting enzyme (ACE), during imatinib mesylate treatment of patients with chronic myeloid leukaemia (CML). Expressions of RAS components were studied in patients with CML at the time of diagnosis ( n = 83) and at 3, 6 and 12 months after diagnosis ( n = 35) by quantitative real-time polymerase chain reaction. De novo CML patients had increased ACE, angiotensinogen and renin mRNA levels and these expression levels decreased following administration of imatinib. The RAS activities were significantly different among Sokal risk groups of CML, highlighting the altered biological activity of RAS in neoplastic disorders. The results of this study confirm that haematopoietic RAS affects neoplastic cell production, which may be altered via administration of tyrosine kinase inhibitors such as imatinib mesylate.

Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients

Leukemia ◽  
2013 ◽  
Vol 28 (3) ◽  
pp. 702-705 ◽  
Author(s):  
C H Kok ◽  
T Leclercq ◽  
D B Watkins ◽  
V Saunders ◽  
J Wang ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
De Novo ◽  
Molecular Response

Gemtuzumab-ozogamicin and blinatumomab as treatment for refractory mixed-phenotype blast crisis in chronic myeloid leukaemia

2021 ◽  
Vol 14 (11) ◽  
pp. e243745
Author(s):  
Roberto Ovilla-Martinez ◽  
Luis Alejandro Weber Sánchez ◽  
Xóchitl Cota-Rangel ◽  
Pamela Elena Baez-Islas
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Poor Prognosis ◽  
Conventional Treatment ◽  
Kinase Inhibitor ◽  
Blast Crisis ◽  
Gemtuzumab Ozogamicin ◽  
Blast Phase ◽  
Uncommon Presentation ◽  
Mixed Phenotype

In the tyrosine kinase inhibitor era, the blast phase of chronic myeloid leukaemia (BP-CML) renders an uncommon presentation and has a poor prognosis with an estimated overall survival below 20%. Mixed-phenotype blast phase is even more infrequent, presenting in 3.3% of these patients. Blast phase manifests along haematological sarcomas, with extramedullary activity in lymph nodes, skin and bone. We report the case of a patient with an ovarian sarcoma as an extramedullary presentation of mixed-phenotype BP-CML refractory to conventional treatment which responded to immunotherapy against CD33 and CD19.

Sign in / Sign up

Export Citation Format

Share Document